Spironolactone, but not Eplerenone, Impairs Glucose Tolerance in a Rat Model of Metabolic Syndrome
Open Access
- 1 January 2012
- journal article
- Published by Japanese Society of Veterinary Science in Journal of Veterinary Medical Science
- Vol. 74 (8) , 1015-1022
Abstract
Although some clinical studies have suggested that spironolactone (SPL), a mineralocorticoid receptor (MR) antagonist, appears to increase the blood glucose levels, experimental studies have not supported this notion. Here, we investigated the effect of SPL on blood glucose levels in SHR/NDmcr-cp(cp/cp) (ND) rats, an animal model of metabolic syndrome, in comparison with that of eplerenone (EPL), another MR antagonist. At the same dose of 100 mg/kg, SPL and EPL increased the urinary sodium-to-potassium ratio to a comparable extent, indicating that both agents have similar renal MR antagonistic efficacy in ND rats. Interestingly, SPL but not EPL significantly increased the level of blood glucose. The oral glucose tolerance test revealed that treatment with SPL led to glucose intolerance. The levels of serum insulin and adiponectin, regulators of the blood glucose level, were virtually unaffected by treatment with SPL. On the other hand, SPL induced a marked increase in the blood level of aldosterone, known to be a risk factor for insulin resistance. These results demonstrate that in comparison with EPL, SPL characteristically impairs glucose tolerance in an animal model of metabolic syndrome, in association with a higher blood level of aldosterone.Keywords
This publication has 34 references indexed in Scilit:
- Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney diseaseKidney International, 2011
- The Role of Aldosterone in the Metabolic SyndromeCurrent Hypertension Reports, 2011
- Antiadipogenic Effects of the Mineralocorticoid Receptor Antagonist Drospirenone: Potential Implications for the Treatment of Metabolic SyndromeEndocrinology, 2011
- A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist ActivityHypertension, 2008
- Primary aldosteronismCurrent Cardiology Reports, 2007
- Effect of Spironolactone on Blood Pressure in Subjects With Resistant HypertensionHypertension, 2007
- Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetesDiabetologia, 2004
- The effect of aldosterone on glucose metabolismCurrent Hypertension Reports, 2003
- Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)Cardiovascular Drug Reviews, 2001
- Effect of Dietary Carbohydrates on Insulin and Glucagon Receptors in a New Model of Noninsulin-Dependent Diabetes-SHR/N-Corpulent RatExperimental Biology and Medicine, 1989